Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | REGN5668 |
Trade Name | |
Synonyms | REGN 5668|REGN-5668 |
Drug Descriptions |
REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary). |
DrugClasses | MUC16 Targeted Therapy 10 |
CAS Registry Number | NA |
NCIT ID | C176028 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cemiplimab + REGN5668 | Cemiplimab REGN5668 | 0 | 1 |
REGN4018 + REGN5668 | REGN4018 REGN5668 | 0 | 1 |
REGN5668 | REGN5668 | 0 | 0 |